Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein

T C Rodman, S E To, H Hashish, K Manchester, T C Rodman, S E To, H Hashish, K Manchester

Abstract

We have previously shown that IgM antibodies that react with human immunodeficiency virus (HIV) Tat, a regulatory protein essential for viral replication, are present in sera of all normal, HIV-negative individuals and deficient in sera of HIV-positive individuals at progressively greater frequency as diagnosis of AIDS nears. That IgM was designated as a set of natural antibodies, a repertoire of the normal humoral immune system believed to provide early defense against infectious invaders. In the prior study, by means of a series of synthetic peptides representing the amino acid sequence of HIV-1 Tat, one epitope for the IgM natural antibodies was defined within the cysteine-rich domain, shown in cell transfection studies to participate in Tat function. In this study we have defined another epitope, within the basic domain, with which the natural antibodies react. The specific sequence and amino acid residues required for that epitope are coincident with those required for the role of Tat in viral replication. The IgM antibodies reactive with the two epitopes of Tat make up two distinct sets, which, together, account for the total Tat reactivity of both HIV-negative and HIV-positive sera. The striking coincidence of the two epitopes with the two functional sequences of Tat suggests a potential role of those natural antibodies in control of HIV pathogenesis. By inference from the extensive evidence for the presence of extracellular Tat in cultures of HIV-infected cells, Tat may be expected to be present in the circulating plasma of infected people. We propose, therefore, that the Tat-reactive natural antibodies, documented in these studies to be present in the circulating plasma in the pre-AIDS stages of HIV infection, may inhibit cell entry of plasma-borne Tat and thereby curtail HIV propagation. Thus, those natural antibodies may be a host factor for delay in HIV pathogenetic progression.

References

    1. Science. 1992 Oct 30;258(5083):803-5
    1. J Exp Med. 1992 May 1;175(5):1247-53
    1. Blood. 1992 Dec 15;80(12):3036-43
    1. Proc Natl Acad Sci U S A. 1993 Feb 15;90(4):1571-5
    1. Adv Immunol. 1966;5:1-28
    1. J Immunol. 1982 Jun;128(6):2779-87
    1. Biochemistry. 1982 Sep 28;21(20):5020-31
    1. Science. 1985 Jun 7;228(4704):1211-5
    1. Eur J Biochem. 1986 Apr 1;156(1):5-8
    1. Immunol Rev. 1986 Dec;94:99-112
    1. J Exp Med. 1988 Mar 1;167(3):1228-46
    1. Science. 1988 Apr 1;240(4848):70-3
    1. Clin Exp Immunol. 1988 Mar;71(3):410-6
    1. Immunol Rev. 1988 Oct;105:5-26
    1. Cell. 1988 Dec 23;55(6):1189-93
    1. Science. 1989 Mar 3;243(4895):1184-8
    1. Annu Rev Immunol. 1989;7:513-35
    1. Proc Natl Acad Sci U S A. 1989 Oct;86(19):7397-401
    1. Adv Immunol. 1989;47:377-431
    1. J Virol. 1990 Feb;64(2):962-5
    1. J Virol. 1990 Apr;64(4):1864-8
    1. Nature. 1990 May 3;345(6270):84-6
    1. J Med Virol. 1990 Mar;30(3):163-8
    1. Science. 1990 Sep 14;249(4974):1281-5
    1. Proc Natl Acad Sci U S A. 1990 Sep;87(18):7030-4
    1. Cell. 1990 Nov 16;63(4):655-7
    1. Clin Immunol Immunopathol. 1990 Dec;57(3):430-40
    1. Proc Natl Acad Sci U S A. 1990 Nov;87(22):8985-9
    1. J Acquir Immune Defic Syndr. 1991;4(2):165-72
    1. Cell. 1991 Jan 25;64(2):351-63
    1. J Immunol Methods. 1991 Mar 1;137(1):27-35
    1. Proc Natl Acad Sci U S A. 1991 May 1;88(9):4045-9
    1. EMBO J. 1991 Jul;10(7):1733-9
    1. EMBO J. 1991 Aug;10(8):2311-8
    1. Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6234-8
    1. J Biol Chem. 1991 Aug 25;266(24):16128-34
    1. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7635-9
    1. J Virol. 1993 Jan;67(1):277-87

Source: PubMed

3
Předplatit